Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:LXRX
  • CUSIP: 52887210
  • Web: www.lexpharma.com
Capitalization:
  • Market Cap: $1.30816 billion
  • Outstanding Shares: 105,581,000
Average Prices:
  • 50 Day Moving Avg: $14.41
  • 200 Day Moving Avg: $15.27
  • 52 Week Range: $11.80 - $19.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.10
  • P/E Growth: -0.16
Sales & Book Value:
  • Annual Revenue: $81.1 million
  • Price / Sales: 16.34
  • Book Value: $1.01 per share
  • Price / Book: 12.43
Profitability:
  • EBIDTA: ($140,120,000.00)
  • Net Margins: -170.63%
  • Return on Equity: -94.87%
  • Return on Assets: -31.59%
Debt:
  • Debt-to-Equity Ratio: 0.80%
  • Current Ratio: 1.86%
  • Quick Ratio: 1.85%
Misc:
  • Average Volume: 689,338 shs.
  • Beta: 0.26
  • Short Ratio: 31.12
 

Frequently Asked Questions for Lexicon Pharmaceuticals (NASDAQ:LXRX)

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.12. The business earned $12 million during the quarter, compared to analysts' expectations of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The business's revenue was down 40.3% on a year-over-year basis. During the same period last year, the company posted ($0.37) EPS. View Lexicon Pharmaceuticals' Earnings History.

When will Lexicon Pharmaceuticals make its next earnings announcement?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Lexicon Pharmaceuticals.

Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2017?

4 analysts have issued 1-year target prices for Lexicon Pharmaceuticals' shares. Their predictions range from $21.00 to $39.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $28.75 in the next twelve months. View Analyst Ratings for Lexicon Pharmaceuticals.

What are analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

  • 1. Cowen and Company analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)
  • 2. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (7/18/2017)
  • 3. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
  • 4. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)

Who are some of Lexicon Pharmaceuticals' key competitors?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the folowing people:

  • Raymond Debbane, Independent Chairman of the Board
  • Lonnel Coats, President, Chief Executive Officer, Director
  • Jeffrey L. Wade J.D., Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
  • Pablo Lapuerta M.D., Executive Vice President, Chief Medical Officer
  • Alan J. Main Ph.D., Executive Vice President - CMC and Supply Operations
  • Alexander A. Santini, Executive Vice President, Chief Commercial Officer
  • Praveen Tyle Ph.D., Executive Vice President - Research and Development
  • James F. Tessmer, Vice President - Finance & Accounting
  • Philippe J. Amouyal, Independent Director
  • Samuel L. Barker Ph.D., Independent Director

Who owns Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Artal Group S.A. (54.48%), FMR LLC (14.95%), Ulys L.L.C. (4.09%), Vanguard Group Inc. (3.51%), USS Investment Management Ltd (3.32%) and Eagle Asset Management Inc. (2.71%). Company insiders that own Lexicon Pharmaceuticals stock include James F Tessmer, Lonnel Coats and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Teachers Retirement System of The State of Kentucky, Alliancebernstein L.P., GSA Capital Partners LLP, Virginia Retirement Systems ET AL, TIAA CREF Investment Management LLC, Bank of Montreal Can and Bank of New York Mellon Corp. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, Pinnacle Associates Ltd., State Street Corp, Voya Investment Management LLC, DekaBank Deutsche Girozentrale, Quantitative Investment Management LLC, FMR LLC and OxFORD Asset Management LLP. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Lonnel Coats and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

How do I buy Lexicon Pharmaceuticals stock?

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $12.55.


MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $28.75 (129.08% upside)

Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Needham & Company LLCReiterated RatingBuy$21.00MediumView Rating Details
8/7/2017WedbushReiterated RatingOurperform$39.00LowView Rating Details
8/1/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
5/3/2017HC WainwrightSet Price TargetBuy$27.00HighView Rating Details
3/7/2017Citigroup Inc.Boost Price TargetBuy$24.00 -> $28.00N/AView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$25.00 -> $26.00N/AView Rating Details
5/5/2016J P Morgan Chase & CoReiterated RatingHold$16.00N/AView Rating Details
9/28/2015GabelliUpgradeSell -> Hold$13.50N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Earnings by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Earnings History by Quarter for Lexicon Pharmaceuticals (NASDAQ LXRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.36)N/AView Earnings Details
8/1/2017Q2 2017($0.45)($0.33)$18.34 million$12.00 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.51)($0.31)$15.56 million$23.00 millionViewN/AView Earnings Details
11/1/2016Q316($0.50)($0.35)$9.68 million$27.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.40)($0.37)$12.36 million$20.10 millionViewN/AView Earnings Details
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details
11/6/2015Q3($0.36)($0.34)$0.44 million$0.57 millionViewN/AView Earnings Details
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details
11/4/2014Q3($0.05)($0.05)$0.16 million$0.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details
11/12/2013Q3($0.01)($0.06)$1.59 million$0.24 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.22 millionViewN/AView Earnings Details
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
2017 EPS Consensus Estimate: ($1.70)
2018 EPS Consensus Estimate: ($1.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.47)($0.47)($0.47)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.46)($0.46)($0.46)
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.41)($0.41)($0.41)
Q3 20181($0.34)($0.34)($0.34)
Q4 20181($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Insider Ownership Percentage: 5.77%
Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Lonnel CoatsInsiderBuy30,000$12.54$376,200.00View SEC Filing  
9/15/2017Sam L BarkerDirectorBuy1,000$12.50$12,500.00View SEC Filing  
6/6/2016James F TessmerVPSell1,500$15.00$22,500.00View SEC Filing  
5/23/2016James F TessmerVPSell6,000$13.00$78,000.00View SEC Filing  
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Source:
DateHeadline
americanbankingnews.com logo Analysts Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Quarterly Sales of $33.98 Million
www.americanbankingnews.com - September 21 at 5:12 AM
streetinsider.com logoLexicon Pharma (LXRX) Granted European Commission Approval for XERMELO (Telotristat Ethyl) - StreetInsider.com
www.streetinsider.com - September 20 at 5:40 AM
nasdaq.com logoLexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $376200 of Shares - Nasdaq
www.nasdaq.com - September 20 at 5:40 AM
finance.yahoo.com logoEuropean Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy
finance.yahoo.com - September 20 at 5:40 AM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - September 19 at 4:26 PM
finance.yahoo.com logoLexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 8:07 PM
americanbankingnews.com logoLonnel Coats Buys 30,000 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) Stock
www.americanbankingnews.com - September 18 at 7:23 AM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Director Sam L. Barker Buys 1,000 Shares
www.americanbankingnews.com - September 18 at 7:23 AM
americanbankingnews.com logoLexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:48 AM
seekingalpha.com logoLexicon Thumped Despite Favorable Data - Seeking Alpha
seekingalpha.com - September 16 at 6:14 AM
finance.yahoo.com logoSlashing Fair Value Estimate on Lexicon Pharmaceuticals
finance.yahoo.com - September 16 at 6:13 AM
fool.com logoWhy Lexicon Pharmaceuticals Is Down 11% Today
www.fool.com - September 14 at 12:46 PM
nasdaq.com logoLexicon Pharmaceuticals is Now Oversold (LXRX)
www.nasdaq.com - September 14 at 7:24 AM
finance.yahoo.com logoNew England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes
finance.yahoo.com - September 13 at 6:19 AM
streetinsider.com logoLexicon Pharma (LXRX) Announces Four Data Presentations at ESMO - StreetInsider.com
www.streetinsider.com - September 9 at 5:56 AM
streetinsider.com logoLexicon Pharma (LXRX) Announces Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 ... - StreetInsider.com
www.streetinsider.com - September 9 at 5:56 AM
finance.yahoo.com logoLexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin
finance.yahoo.com - September 9 at 5:56 AM
finance.yahoo.com logoLexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference
finance.yahoo.com - September 8 at 2:36 AM
finance.yahoo.com logoLexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
finance.yahoo.com - September 8 at 2:36 AM
finance.yahoo.com logoLexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
finance.yahoo.com - September 5 at 4:18 PM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 4:32 AM
seekingalpha.com logoLexicon Pharmaceuticals: Stock Out Of Favor But Fundamentals Improving - Seeking Alpha
seekingalpha.com - August 27 at 7:26 PM
nasdaq.com logoNotable Monday Option Activity: LXRX, NFLX, PRLB
www.nasdaq.com - August 21 at 7:44 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
finance.yahoo.com - August 18 at 6:32 AM
streetinsider.com logoLexicon Pharma (LXRX) Reports Additional Positive Data From ... - StreetInsider.com
www.streetinsider.com - August 16 at 5:58 AM
finance.yahoo.com logoLexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
finance.yahoo.com - August 16 at 5:58 AM
americanbankingnews.com logo-$0.32 EPS Expected for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) This Quarter
www.americanbankingnews.com - August 13 at 4:16 PM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 11 at 10:56 AM
americanbankingnews.com logoEquities Analysts Set Expectations for Lexicon Pharmaceuticals, Inc.'s FY2017 Earnings (NASDAQ:LXRX)
www.americanbankingnews.com - August 9 at 8:52 AM
nasdaq.com logoOversold Conditions For Lexicon Pharmaceuticals (LXRX) - Nasdaq ... - Nasdaq
www.nasdaq.com - August 9 at 3:49 AM
americanbankingnews.com logoFY2019 Earnings Estimate for Lexicon Pharmaceuticals, Inc. Issued By Wedbush (NASDAQ:LXRX)
www.americanbankingnews.com - August 8 at 1:06 PM
americanbankingnews.com logoWedbush Reaffirms Ourperform Rating for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
www.americanbankingnews.com - August 7 at 11:20 AM
seekingalpha.com logoLexicon Likely Stuck For A Little While - Seeking Alpha
seekingalpha.com - August 5 at 2:14 AM
finance.yahoo.com logoLexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 4 at 1:03 AM
finance.yahoo.com logoLexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update
finance.yahoo.com - August 3 at 3:55 AM
finance.yahoo.com logoLexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : August 1, 2017
finance.yahoo.com - August 3 at 3:55 AM
finance.yahoo.com logoLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : August 2, 2017
finance.yahoo.com - August 3 at 3:55 AM
finance.yahoo.com logoEdited Transcript of LXRX earnings conference call or presentation 1-Aug-17 12:00pm GMT
finance.yahoo.com - August 3 at 3:55 AM
prnewswire.com logoLexicon Pharmaceuticals Announces Opt-In Decision For US Co-Promotion Of Sotagliflozin With Sanofi In Type 1 ... - PR Newswire (press release)
www.prnewswire.com - August 2 at 3:29 AM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Hold Rating from Cowen and Company
www.americanbankingnews.com - August 1 at 2:08 PM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Posts Earnings Results, Beats Expectations By $0.11 EPS
www.americanbankingnews.com - August 1 at 10:47 AM
finance.yahoo.com logoLexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 Diabetes
finance.yahoo.com - July 31 at 7:59 PM
americanbankingnews.com logo$17.60 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
www.americanbankingnews.com - July 28 at 4:57 PM
americanbankingnews.com logoComparing Intec Pharma (NTEC) & Lexicon Pharmaceuticals (LXRX)
www.americanbankingnews.com - July 28 at 12:33 PM
americanbankingnews.com logoZacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Announce -$0.45 EPS
www.americanbankingnews.com - July 26 at 12:40 PM
prnewswire.com logoLexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1 ... - PR Newswire (press release)
www.prnewswire.com - July 24 at 12:40 PM
finance.yahoo.com logoLexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1, 2017
finance.yahoo.com - July 24 at 12:40 PM
streetinsider.com logoLexicon Pharma (LXRX) in Collaboration with Ipsen Granted ... - StreetInsider.com
www.streetinsider.com - July 22 at 6:17 AM
streetinsider.com logoLexicon Pharma (LXRX) in Collaboration with Ipsen Granted ... - StreetInsider.com
www.streetinsider.com - July 22 at 6:17 AM
finance.yahoo.com logoLexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)
finance.yahoo.com - July 22 at 6:17 AM

Social

Chart

Lexicon Pharmaceuticals (LXRX) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff